FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Fate Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
City of Hope Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
City of Hope Medical Center
University of Washington
Allogene Therapeutics
Case Comprehensive Cancer Center
Ossium Health, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Ohio State University Comprehensive Cancer Center
AIDS Malignancy Consortium
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Celgene
Mayo Clinic
The Second Affiliated Hospital of Fujian Medical University
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
University of Chicago
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
St. Jude Children's Research Hospital
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Sana Biotechnology
Baylor College of Medicine
Case Comprehensive Cancer Center
University of Arizona
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital
Medical College of Wisconsin
Mayo Clinic
City of Hope Medical Center
Sana Biotechnology
City of Hope Medical Center
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
Jonsson Comprehensive Cancer Center
CStone Pharmaceuticals